KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $1.7 billion.

  • Moderna's Total Current Liabilities fell 2362.56% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 2362.56%. This contributed to the annual value of $2.2 billion for FY2024, which is 2683.25% down from last year.
  • According to the latest figures from Q3 2025, Moderna's Total Current Liabilities is $1.7 billion, which was down 2362.56% from $1.6 billion recorded in Q2 2025.
  • Moderna's 5-year Total Current Liabilities high stood at $10.0 billion for Q3 2021, and its period low was $1.6 billion during Q2 2025.
  • Its 5-year average for Total Current Liabilities is $4.9 billion, with a median of $3.5 billion in 2023.
  • As far as peak fluctuations go, Moderna's Total Current Liabilities surged by 617201.26% in 2021, and later plummeted by 6212.38% in 2023.
  • Moderna's Total Current Liabilities (Quarter) stood at $9.1 billion in 2021, then crashed by 46.07% to $4.9 billion in 2022, then tumbled by 38.76% to $3.0 billion in 2023, then dropped by 26.83% to $2.2 billion in 2024, then dropped by 23.8% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q3 2025, $1.6 billion for Q2 2025, and $1.6 billion during Q1 2025.